BiotechTube

capecitabine [Xeloda]

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Colorectal Cancer

Conditions

Colorectal Cancer

Trial Timeline

Jul 1, 2007 → Mar 1, 2012

NCT ID
NCT00502671

About capecitabine [Xeloda]

capecitabine [Xeloda] is a approved stage product being developed by Roche for Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00502671. Target conditions include Colorectal Cancer.

What happened to similar drugs?

14 of 20 similar drugs in Colorectal Cancer were approved

Approved (14) Terminated (3) Active (5)
✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
✅Cetuximab (EGFR inhibitor) + Bevacizumab + Irinotecan (CPT-11) + Oxaliplatin + Leucovorin and 5-FU + CapecitabineMerckApproved
✅5-FU based doublet chemotherapy + bevacizumabRocheApproved
✅5-Fluorouracil + Bevacizumab + Irinotecan + OxaliplatinRocheApproved
✅Oxaliplatin + Capecitabine + Bevacizumab + Leucovorin + 5-Fluouracil + IrinotecanRocheApproved
✅CapecitabineRocheApproved
✅CapecitabineRocheApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT01077726Phase 2Completed
NCT00796718Phase 2Completed
NCT00502671ApprovedCompleted
NCT00532948Phase 1Completed

Competing Products

20 competing products in Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
35
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
35
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
11
ALIMTA + OxaliplatinEli LillyPhase 2
35
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
25
Bevacizumab + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 1/2
32
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
31
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOXChugai PharmaceuticalPhase 2/3
38
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
CPT-11 and TS-1 + CPT-11, 5-FU and l-LVDaiichi SankyoPhase 2/3
38
CPT-11 based regimensDaiichi SankyoPre-clinical
26
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)Daiichi SankyoPhase 2
35
Tivantinib + Placebo + Cetuximab + IrinotecanDaiichi SankyoPhase 1/2
32
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3WDaiichi SankyoPhase 2
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
CS-1008 + irinotecanDaiichi SankyoPhase 2
27
CS-7017 + PlaceboDaiichi SankyoPhase 2
27
Patritumab DeruxtecanDaiichi SankyoPhase 2
27
CS-1008 + FOLFIRIDaiichi SankyoPhase 1
29
DS-8273a + nivolumabDaiichi SankyoPhase 1
21